Navigation Links
Diet plays a role in kidney stones

According to a few researchers, lessening calcium in the diet does not help prevent the return of kidney stones. Kidney stones are made of a chemical called calcium oxalate and one approach to preventing this painful condition// is to reduce the amount of calcium in the diet. But since calcium is important for keeping a healthy level of bone density and controlling blood pressure, there needs to be good evidence for its role in protection against kidney stones.

Researchers at the University of Texas, now report upon a comparison of two diets against kidney stones. It involved 100 men with recurrent stones. Half were put on a diet with a normal amount of calcium (15 mmol a day) but reduced animal protein (50 grams a day) and salt (30 mmol a day). The other men had a low calcium diet (12 mmol a day) and both groups were followed up for five years.

After this time, 10 of the men on the normal calcium diet had suffered recurrences compared to 23 on the low calcium diet. Analysis of the urine showed that levels of calcium dropped in both groups. But excretion of oxalate increased in the low calcium group favouring kidney stone formation while it decreased in the normal calcium group. So people with a kidney stone problem would be best advised to reduce animal protein and salt but keep calcium intake normal.


'"/>




Page: 1

Related medicine news :

1. Treadmill test displays hidden heart disease
2. Clotting Protein plays a role in nerve repair
3. Electrocardiograms plays a limited role
4. Lifestyle plays an important role in determining one’s ag
5. Depression plays a vital role in Diabetes
6. Angiotensin-II-receptor blockers - Treat kidney failure
7. Helping the neurology of kidney failure
8. Woman gets cancer from transplanted kidney
9. Vitamin E decreases high blood pressure in kidney failure
10. Filtration treatment assigns more live kidney donation
11. New operation for kidney cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Diet plays role kidney stones

(Date:7/25/2008)...alif., July 25 /PRNewswire/ -- AutoGenomics, Inc. ...tatement on Form S-1 with the,Securities and Excha...blic,offering of shares of its common stock. The n... of which are expected to be offered by,AutoGenomi...ve not yet been,determined., J.P. Morgan Securiti...
(Date:7/25/2008)... The Retina Group of New York will prese...cular degeneration especially designed for seniors...ic Library at 116 Merritts Road, Farmingdale, NY 1...ndance is free and refreshments will be provided. ...-6100. , Hicksville and H...
(Date:7/25/2008)... Columbus-based law firm represents Pick...ef purchased at Columbus-area Kroger store , ...uly 25, 2008 -- http://www.donaheyohioinjurylawye... personal injury law firms in central Ohio, has fi... Court (Case No. 08CV9804) against The Kroger Co.,...
(Date:7/24/2008)...inn., July 24 /PRNewswire-FirstCall/ -- ev3 Inc. (...port its 2008 second quarter and,year-to-date fina... quarter,and year-to-date financial results on Mon...ours., The company will host a conference call an...tern Time) on Tuesday, July 29, 2008. ev3,manageme...
Breaking Medicine News(10 mins):Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Donahey Law Firm Files E. Coli Product Liability Lawsuit Against Kroger Company in Franklin County Court 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2
... the body from tissue damage also increases the ri...gton University School of Medicine in St. Louis te...thy cells // survive the effects of toxic chemothe... found that the protein encourages the growth of t...
...hwestern Medical Center have identified a step tha...a-amyloid that encourages the spread of the diseas...any other essential roles produces too much beta-a...he whole enzyme knocks out many of its other funct...
... and Molecular Biology (CCMB), Hyderabad has unrav... way for detecting the mechanisms that prevent can... Bhadra and Utpal Bhadra have been instrumental be...t a disease, which has remained a global challenge...
...i following the water borne diseases crossed 55 ev...mic. Most of the 55 dead were from the densely pop... last month's floods. Over 1,000 patients had been...with complications arising from leptospirosis, den...
Other Medicine News:Health News:Researchers Identified Process That Aids Spread Of Alzheimer’s’ Disea 2
(Date:7/23/2008)...Body Have Greater Concentrations of,Stem Cells, A...wire/ -- Fat removed,from the lower abdomen and in...xcellent source of stem cells, with higher stem ce...ports a Brazilian-based study in August,s,Plastic ...l journal of the,American Society of Plastic Surge...
(Date:7/23/2008)...all/ -- Dendreon Corporation,(Nasdaq: DNDN ) toda...onitoring Committee (IDMC) to review in October 20...ng to the Company,s Phase 3 IMPACT (IMmunotherapy,...as D9902B) clinical trial,of PROVENGE(R) (sipuleuc...ctive cellular immunotherapy for the treatment of ...
(Date:7/22/2008)...swire-FirstCall/ -- Following a,thorough review th...harmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) to...hase 3 study in liver cancer. Progen confirmed,its...olio of compounds and,the company will actively se...es through Merger & Acquisition activity., The st...
(Date:7/22/2008)...- Nonin Medical, a leading innovator,of physiologi...as entered,the clinical testing phase with its bre...turation. Today,s most common application for this...gional blood oxygenation,in the brain -- cerebral ...n ongoing clinical study at the,Duke University Me...
Breaking Medicine Technology:Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Is Tap Water Safe for Your Dog 3F 20799 1Is Tap Water Safe for Your Dog 3F 20799 2Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 1Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 2Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 3Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 4Mylan Inc Acquires Central Eastern European Generics Businesses of Merck KGaA 20795 1Mylan Inc Acquires Central Eastern European Generics Businesses of Merck KGaA 20795 2IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 1IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 2IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 3IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 4IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 5
...wire/ -- Results from,the primary analysis of a ra...owed that 77 percent of treatment-experienced HIV-...600 mg tablets with,100 mg ritonavir (PREZISTA/r) ...(OBR) of antiretroviral (ARV) agents, reached a,pl...ared to 68,percent of patients taking Kaletra(R)1 ...
...ire-FirstCall/ --,Genzyme Corp. announced top-line... studies to assess the safety and efficacy of,tole...polymer,therapy for patients with Clostridium diff... 3 study of tolevamer liquid is fully,enrolled and...irst Phase 3 study known as the Polymer Alternativ...
Other Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 2Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 3Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 4
Only SurLok combines precise control, enhanced basket and grasper strength, and the added security of a unique wire-locking mechanism. You can feel the difference. The SurLok flat-wire and grasper ha
The SurLok helical stone baskets are constructed of strong and resilient stainless steel. These helical baskets present a spiral profile that effectively clears both stones and fragments.
The 3-way design permits continuous irrigation through a separate irrigation lumen in the Foley Catheter. 3-Way Catheters are available in Latex construction, as well as LUBRICATH coatings, and in a
The Coude tip design facilitates negotiation of the prostatic urethra. It is available in a medium length olive Coude tip with a single drainage eye. The red latex construction provides added stiffne
Medicine Products: